Indivior Plc
INDV
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.35B
Close$
$-1.25
103.5% downside
Current Fair Value
103.5% downsideOvervalued by 103.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.35 Billion |
|---|---|
| Enterprise Value | $4.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.68 |
| Beta | 1.11 |
| Outstanding Shares | 125,352,000 |
Return
| Return on Equity | -175.00% |
|---|---|
| Return on Assets | 21.05% |
| Return on Invested Capital | 81.10% |
Valuation & Multiples
| P/E Ratio | 12.28 |
|---|---|
| PEG | 13.74 |
| Price to Sales | 3.59 |
| Price to Book Ratio | -17.96 |
| Enterprise Value to Revenue | 3.29 |
| Enterprise Value to EBIT | 12.51 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.44 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.89
Average shareholder expectationRevenue Estimate
$307.55 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$1.06
Average shareholder expectationRevenue Estimate
$329.35 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3684▼ 50.46% |
|---|---|
| Total Calls | 2,401,500▲ 672.43% |
| Total Puts | 884,600▲ 225.94% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.83%▼ 4.12% |
|---|---|
| Total Invested | $5.03B▲ 29.18% |
| Investors Holding | 348▲ 51.00% |
ESG Score
No data
About Indivior Plc
CEO: Shaun Thaxter Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...